Jimmy Kang

Jimmy Kang

Auto-generated profile, based on publicly available information

Jimmy Kang

University of Alberta

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
Abdulhakim Al-EzziAbdulhakim Al-Ezzi
Abdulhakim Al-Ezzi
RARebecca Arechavala
Rebecca Arechavala
RBRyan Butler
Ryan Butler
ANAnne Nolty
Anne Nolty
JKJimmy J. Kang
Jimmy J. Kang
XAXianghong Arakaki
Xianghong Arakaki
Alterations in functional connectivity (FC) have been observed in individuals with Alzheimer’s disease (AD) with elevated amyloid (Aβ) and tau. However, it is not yet known whether directed FC is already influenced by Aβ and tau load in cognitively healthy (CH) individuals. A 21-channel electroencephalogram (EEG) was used from 46 CHs classified based on cerebrospinal fluid (CSF) Aβ tau ratio: pathological (CH-PAT) or normal (CH-NAT). Directed FC was estimated with Partial Directed Coherence in frontal, temporal, parietal, central, and occipital regions. We also examined the correlations between directed FC and various functional metrics, including neuropsychology, cognitive reserve, MRI volumetrics, and heart rate variability between both groups. Compared to CH-NATs, the CH-PATs showed decreased FC from the temporal regions, indicating a loss of relative functional importance of the temporal regions. In addition, frontal regions showed enhanced FC in the CH-PATs compared to CH-NATs, suggesting neural compensation for the damage caused by the pathology. Moreover, CH-PATs showed greater FC in the frontal and occipital regions than CH-NATs. Our findings provide a useful and non-invasive method for EEG-based analysis to identify alterations in brain connectivity in CHs with a pathological versus normal CSF Aβ/tau.

2 August 2024 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
NFNicholas M Fialka
Nicholas M Fialka
AWAbeline R Watkins
Abeline R Watkins
AAAbrar Alam
Abrar Alam
RERyaan EL-Andari
Ryaan EL-Andari
JKJimmy J H Kang
Jimmy J H Kang
JNJeevan Nagendran
Jeevan Nagendran
There remains debate over the optimal mitral valve replacement (MVR) option for patients aged 50–70 years. The objective of this study was to retrospectively compare the long-term outcomes of mechanical and bioprosthetic MVR in this patient population. Data from patients undergoing MVR between 2004 and 2018 were retrospectively reviewed. The primary outcome was all-cause mortality. Secondary outcomes included perioperative and late morbidity. Two hundred and eight-six propensity-matched patients (n = 143 mechanical; n = 143 bioprosthetic) aged 50–70 years were included in the final analysis. Maximum follow-up was 15.8 years. There was no significant difference in all-cause mortality between the groups at 30 days, 1 year, 5 years, 10 years, and at the longest follow-up. Patients who underwent mechanical MVR experienced significantly lower rates of postoperative atrial fibrillation (P = 0.001). There were no significant differences in rates of sepsis, acute kidney injury, superficial and deep sternal wound infection, mediastinal bleeding, and permanent pacemaker implantation. At the longest follow-up, there were no differences in myocardial infarction, stroke, heart failure or overall rehospitalization. At the same time point, there was an increased rate of MVR in patients receiving a bioprosthetic valve (P = 0.015). Survival following mechanical and bioprosthetic MVR in patients 50–70 years of age is similar to up to 15 years of follow-up. Bioprosthetic MVR is associated with an increased risk of repeat MVR. Mechanical MVR is not associated with an increased risk of stroke. Valve selection in this patient population requires diligent consideration of structural valve deterioration and subsequent reoperation risk as well as bleeding and thromboembolic risk.

1 June 2022 in The Journal of Cardiovascular Surgery
Verified
Journal Article
Closed access
NFNicholas M. Fialka
Nicholas M. Fialka
SBSabin J. Bozso
Sabin J. Bozso
RERyaan EL-Andari
Ryaan EL-Andari
JKJimmy J. Kang
Jimmy J. Kang
AOAndrew O’connell
Andrew O’connell
JNJeevan Nagendran
Jeevan Nagendran
Article: Sex differences in acute type A aortic dissection: a systematic review and meta-analysis - The Journal of Cardiovascular Surgery 2022 Jun 10 - Minerva Medica - Journals

17 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
RERyaan EL-Andari
Ryaan EL-Andari
NFNicholas Fialka
Nicholas Fialka
JKJimmy Kang
Jimmy Kang
YHYongzhe Hong
Yongzhe Hong
PKPadma Kaul
Padma Kaul
JNJayan Nagendran
Jayan Nagendran
Background: Coronary artery bypass grafting (CABG) has been associated with reduced mortality, myocardial infarction, and repeat revascularization compared with percutaneous coronary intervention (PCI) for patients with 3‐vessel coronary artery disease (CAD) and diabetes. The majority of previous studies have been limited to follow‐up of <10 years. Herein, we compared CABG and PCI in patients with 3‐vessel coronary artery disease and diabetes with a maximum long‐term follow‐up of 14 years. Methods: Patients with diabetes and 3‐vessel coronary artery disease but without ST‐segment–elevation myocardial infarction who underwent coronary angiography followed by CABG or PCI from 2009 to 2018 were included in this study. The primary outcome was mortality, and the secondary outcomes included myocardial infarction, stroke, or repeat revascularization. Outcomes were adjusted for age, sex, and clinical comorbidities. Results: A total of 1210 patients underwent PCI (median follow‐up, 9.1 years) while 477 underwent CABG (median follow‐up, 8.1 years). Patients who underwent CABG were less likely to experience mortality (49.6% versus 57.6%, P =0.003, adjusted hazard ratio [aHR], 0.75 [95% CI, 0.61–0.91]), myocardial infarction (15.6% versus 28.1%, P <0.001, aHR, 0.45 [95% CI, 0.33–0.61]), or require repeat revascularization (7.7% versus 26.9%, P <0.001, aHR, 0.21 [95% CI, 0.14–0.30]) at longest follow‐up. Risk of rehospitalization (82.6% versus 83.4%, P =0.656) and stroke (11.6% versus 12.2%, P =0.794) did not significantly differ between groups. Conclusions: In this study, we describe one of the longest follow‐up periods for patients with diabetes and 3‐vessel coronary artery disease who underwent CABG or PCI and confirmed that the shorter‐term benefits seen in randomized trials do translate into longer‐term reductions in risk of death, myocardial infarction, or repeat revascularization.

24 March 2024 in CJC Open
Verified
Journal Article
Open access
JKJimmy J.H. Kang
Jimmy J.H. Kang
MMMichael C MOON
Michael C MOON

17 November 2023 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
RERyaan EL-Andari
Ryaan EL-Andari
NFNicholas M. Fialka
Nicholas M. Fialka
JKJimmy Kang
Jimmy Kang
SBSabin J. Bozso
Sabin J. Bozso
JNJayan Nagendran
Jayan Nagendran
JNJeevan Nagendran
Jeevan Nagendran